TOVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Theriva Biologics Inc (TOVX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive catalysts, has weak financial performance, and no significant trading signals or trends to support a bullish outlook. Additionally, technical indicators and stock trends suggest a potential decline in price over the short term.
The MACD is slightly positive but contracting, RSI is neutral at 41.18, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 0.193, with support at 0.173 and resistance at 0.213. Short-term trends suggest a likelihood of price decline.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Weak financial performance with a significant YoY drop in net income (-43.55%) and EPS (-93.39%). No recent news or events to drive positive sentiment. Stock trend analysis indicates a potential price decline in the short term.
In Q3 2025, the company reported zero revenue growth, a 43.55% YoY decline in net income, and a 93.39% YoY drop in EPS. Gross margin remains at 0, showing no improvement.
No analyst rating or price target data available.
